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Abstract
Introduction: The new coronavirus (SARS-CoV-2) pandemic has shown to
cause even more severe problems among pregnant women, increasing the incidence
of complications before and after childbirth, especially cardiorespiratory problems,
such as the Severe Acute Respiratory Syndrome (SARS). Objectives: To describe
the clinical outcome of SARS caused by SARS-CoV-2 in Brazilian pregnant women
and to compare the rates of morbidity and mortality from other causes in this
group, stratified by the following variables: gestational age and age group. Meth-
odology: Observational, analytical study based on documents whose data were
collected from the 2020 Epidemiological Report No. 40 in the database of the
Brazilian Department of Health, from which morbidity and mortality data were
extracted to calculate the lethality rate and compare rates using a binomial test with
a significance level of 0.05. Results: Of the total number of pregnant women
hospitalized for SARS, 4,467 (46.6%) were confirmed for COVID-19 and, of these,
233 died, corresponding to a lethality rate of 5.2%. Morbidity was higher in the third
trimester of pregnancy, but the disease was more severe in the second trimester
(7%), being worse in women aged 40 years and older (40–49; 8.7% and 50–59;
15.3%). A significant difference was observed in the rate of cases between the
COVID-19 SARS group and the group with other causes in all gestational strata and
age groups. As for deaths, a significant difference was found in the rates between
the first and third trimesters, and in pregnant women aged 10 to 19 years. Conclu-
sion: Considering the variables under analysis, evidence shows that pregnant
women at an advanced age and in the second trimester of pregnancy contribute to
the lethal outcome of the disease. Other variables associated with the presence of
comorbidities and quality of care for pregnant women should be considered in the
model in future studies.
Keywords: SARS, COVID-19, pregnant women, lethality, complications
1
1. Introduction
Originating in the province of Wuhan (China) in December 2019, the corona-
virus known as SARS-CoV-2 became a worldwide public concern, as warned by
the World Health Organization, for its ability to cause severe respiratory tract
infections. COVID-19, a disease caused by such etiologic agent, presents fever,
cough, expectoration, headache, myalgia or fatigue, and diarrhea as the most
common symptoms, and may progress to Severe Acute Respiratory Syndrome
(SARS) [1]. This respiratory complication signals the potential of the pathogen to
cause respiratory failure, the risks of which can be lethal and exacerbated by the
presence of comorbidities, such as hypertension, diabetes mellitus, and cardio-
vascular diseases [2].
COVID-19 has already infected 122,813,796 people and caused the death of
2,709,640, according to weekly epidemiological data provided by the World Health
Organization on March 20, 2021 [3]. Also, according to the 55th Epidemiological
Report released by the Brazilian Department of Health, Brazil has the second
highest number of accumulated cases worldwide (11,950,459), as well as the num-
ber of accumulated deaths (292,752) [4].
Pregnant women are part of this worrying scenario. They are commonly in
contact with healthcare professionals and attend medical facilities, representing one
of the groups most physiologically susceptible to cardiorespiratory complications,
such as hypoxia, and changes in lung volume and functional capacity, especially
when they show common signs and symptoms of COVID-19 that make diagnosis
difficult, such as dyspnea [5].
In Brazil, a review conducted from January 1 to March 20, 2021 (from the
Epidemiological Week – EW 01/2021 to 11/2021), shows that of the 353,277 cases
hospitalized due to SARS, about 2,746 individuals were pregnant women, and 1,491
pregnant women (54.3%) were affected by COVID-19. The Southeast region corre-
sponds to the Brazilian region with the highest number of pregnant women affected
by SARS (1,063 cases or 38.7%), followed by the Northeast region (519 cases or
18.9%). The most representative states in these regions are São Paulo, Ceará, Minas
Gerais, and Rio de Janeiro. The most affected age group was 20–29 years (40.9%),
followed by pregnant women aged 30–39 years (40.2%), with the third trimester of
pregnancy being the period with the highest concentration of cases [4].
Pregnant women with SARS are at risk of death mainly because of progressive
respiratory failure and severe sepsis due to the physiological susceptibility to infec-
tions during pregnancy [5]. Thus, SARS evolved to death in 3.6% of the 9,500
pregnant women covered by the Special Epidemiological Report of EW 11/2021, of
which 90.2% were confirmed to have been infected with COVID-19. Also, the
highest number of cases was in the Southeast and North regions (36.4 and 25.8%,
respectively), affecting a larger number of pregnant women aged 30–39 years,
corresponding to 42.1% [4, 6].
Given the worrisome healthcare scenario described, this study aims to describe
the clinical outcomes of SARS due to SARS-CoV-2 in Brazilian pregnant women and
to compare the morbidity and mortality rates due to other causes in this group,
stratified by the variables: gestational age and age group.
2. Methodology
This is an observational analytical study based on documents, whose data were
collected in the database of the Brazilian Department of Health, precisely in the
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2020 Special Epidemiological Report No. 40 (https://www.gov.br/saude/pt-br/a
ssuntos/media/pdf/2020/dezembro/11/boletim_epidemiologico_covid_40-1.pdf).
The proposed document has a consolidated report on the number of cases and
deaths from COVID-19 in specific groups, including pregnant women affected by
SARS, the object of analysis in this study. The information contained in the Report
included data accumulated up to Epidemiological Week - EW 49 (11/29/2020 to
12/05/2020).
The study variables were the age group and gestational age of the pregnant
women, stratified by cases and deaths in two groups: SARS caused by COVID-19
and SARS caused by other etiologic agents, such as the influenza virus, other viruses
of the respiratory system, and unidentified cases. This grouping of cases caused by
etiological agents is done by the Brazilian Department of Health itself. The age of
the pregnant women was divided into five age groups (10–19 years, 20–29 years,
30–39 years, 40–49 years, and 50–59 years), and gestational age into four categories
(first, second, third trimester, and unidentified). Cases under investigation were
not included in the specified sample.
Initially, a descriptive analysis was performed to present the absolute and rela-
tive frequency of cases and deaths at the age and gestational age strata of pregnant
women distributed in the two groups: SARS caused by COVID-19 and SARS caused
by other etiologic agents. To learn the severity degree of the disease by the study
categories (age group and gestational age), the lethality coefficient was calculated
according to the following formula:
L %ð Þ ¼ Number of deaths SARS caused by COVID19
Number of deaths SARS caused by COVID19
Number of diagnosed cases of SARS caused COVID19
 100: (1)
The rates of cases and deaths in the referred categories were compared using the
binomial test at the level of 5%, with the aid of BioEstat 5.3 software. Sample 1 size, total
number of confirmed SARS cases due to COVID-19, and number of successful cases in
each stratum analyzed were considered. The same was employed for sample 2 with
cases of SARS caused by other agents. The same procedure was carried out for deaths.
The research respected the ethical aspects of research with human beings,
described in the Resolution of the National Health Council 510/16, on the guidelines
and regulatory standards for research in human and social sciences. It provides for
the waiver of consideration by an Ethics Committee when using data available in
the public domain [7]. The ethical criteria of the Declaration of Helsinki and inter-
national standards were observed.
3. Results
Table 1 shows the number of cases and deaths of pregnant women with SARS
diagnosed with COVID-19 (sample 1), as well as other causes (sample 2). In sample
1, 4,467 cases with 233 deaths were reported and in sample 2, 4,268 cases with 101
deaths. Excluding the number of pregnant women of unknown age, the stratum
with the highest prevalence of cases and deaths in sample 1 was the stratum of 20–
39 years (3,647 and 183, respectively), corresponding to about 82 and 78.5%,
respectively. In sample 2, 3,309 cases (77.7%) and 76 deaths (75.2%) were reported
in that age group, a number significantly lower than that in sample 1 (p < 0.05).
However, the highest rate of deaths occurred more significantly in the stratum of
10–19 years as a result of causes other than COVID-19 (p = 0.028).
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As for gestational age, the third trimester showed the highest prevalence of
SARS, and the number of SARS cases due to SARS-CoV-2 was significantly higher
(p < 0.0001). However, the prevalence was significantly higher in the sample of
pregnant women with SARS due to other causes/etiologic agents in the first and
second trimesters (Table 2).
Concerning deaths, Table 2 shows that the lowest rate of deaths occurred in the
first trimester, excluding when gestational age was not identified in either sample,
being significantly lower in sample 2 (p = 0.0051). However, in the third trimester,










Cases 10–19 434 9.7 687 16.1 p < 0.0001
20–29 1863 41.7 2003 47.1 p < 0.0001
30–39 1784 40.0 1306 30.7 p < 0.0001
40–49 311 7.0 218 5.1 p = 0.0003
50–59 72 1.6 42 1.0 p = 0.0101
Deaths 10–19 12 5.2 12 11.9 p = 0.0287
20–29 77 33.0 39 38.6 p = 0.3264
30–39 106 45.5 37 36.6 p = 0.1328
40–49 27 11.6 6 5.9 p = 0.1121
50–59 11 4.7 7 6.9 p = 0.4114
Total — 233 100 101 100 —
*Three cases with unidentified age group were excluded from this analysis.
Source: Authors, 2020 [4] based on data from BRASIL (2020).
Table 1.
Absolute and relative frequencies of SARS cases and deaths in pregnant women notified in Brazil (2020),
according to maternal age.
Data Gestational age
(trimesters)
SARS due to COVID-
19 – confirmed




Cases 1st 384 8.6 553 13.0 p < 0.0001
2nd 1018 22.8 1208 28.3 p < 0.0001
3rd 2784 62.3 2284 53.5 p < 0.0001
Unidentified 281 6.3 223 5.2 p = 0.0328
Total — 4467 100 4268 100 —
Deaths 1st 16 6.9 17 16.8 p = 0.0051
2nd 71 30.5 32 31.7 p = 0.8258
3rd 133 57.0 43 42.6 p = 0.0147
Unidentified 13 5.6 9 8.9 p = 0.2596
Total — 233 100 101 100 —
Source: Authors, 2020 [4] based on data from BRASIL (2020).
Table 2.
Absolute and relative frequencies of SARS cases and deaths in pregnant women notified in Brazil (2020),
according to gestational age.
4
Contemporary Developments and Perspectives in International Health Security - Volume 3
Table 3 shows the lethality rates by gestational age. The group of pregnant
women with SARS caused by COVID-19 was observed to have a higher mortality
rate than that of the group of pregnant women with SARS due to other causes (5.2
and 2.3%, respectively). Considering the strata, the event was more severe in the
second trimester (7%) for the first group, whereas it was more significant in the
first trimester (3.1%) for the second one.
Figure 1 shows the relationship between the age of pregnant women and disease
lethality. The lowest rates have been observed to occur in the first stratum (10–
19 years), increasing with age. In group 1 (deaths from SARS caused by COVID-19),











1st 384 16 4.2 553 17 3.1
2nd 1018 71 7.0 1208 32 2.6
3rd 2784 133 4.8 2284 43 1.8
Unidentified 281 13 4.6 223 9 3.8
Total 4467 233 5.2 4268 101 2.3
Table 3.
Lethality in pregnant women due to SARS caused by COVID-19 and other causes, according to gestational age
in Brazil (2020).
Figure 1.
Distribution of lethality rates by age in the groups of pregnant women with SARS caused by COVID-19 and
SARS due to other causes (BRASIL, 2020).
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In all age groups from group 2 (deaths from SARS due to other causes), the lethality
rate was lower than in group 1, except for the 50–59 age group (16.7%).
4. Discussion
Susceptibility to respiratory pathogens and severe cases of pneumonia during
pregnancy occur due to immunological and cardiopulmonary changes that can
make pregnant women more vulnerable to hypoxia [8]. Figure 2 summarizes the
main changes in pregnancy and its susceptibility to COVID-19.
The pulmonary system of pregnant women also undergoes complex changes due
to their pregnancy status. There is a compression of the diaphragm by the uterus,
leading to a decrease in thoracic compliance and total lung capacity [8]. In addition,
pneumonia caused by COVID-19 rapidly progresses from focal to bilateral pulmo-
nary consolidation, predisposing these patients to hypoxemic respiratory failure [5]
(Figure 2). Symptoms started between 5.8 and 29.9 weeks of pregnancy and
between 5.7 and 30.7 weeks of hospital stay [9].
In the cardiovascular system (Figure 2), the pregnant woman undergoes pro-
found physiological changes. There is a myocardial hypertrophy with enlarged
cardiac chambers, which leads to an increase in cardiac output that reaches a
maximum of 30–40% between the 28th and 36th week, when it stabilizes until
childbirth; there is a gradual increase in heart rate that reaches its maximum peak
between the 28th and 36th weeks [10]; total peripheral resistance is reduced by up
to 30% from the 8th–12th week of gestation, remaining at these levels until term
[11]; finally, there is an increase in central venous pressure in the lower portions of
the body, especially from the second trimester onwards, due to the action of the
uterine volume on the pelvic veins and inferior vena cava [12].
This overload of the cardiovascular system becomes dangerous as the pregnant
woman faces the potential aggressions of COVID-19 (Figure 2). According to the
Figure 2.
Actions of SARS-CoV-2 to the cardiovascular, respiratory and immune systems and their physiological
alterations in pregnancy. Source: Authors (2021).
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literature, regardless of being pregnant or not, it is postulated that SARS-CoV-2
causes myocardial damage by at least three mechanisms: (I) Hyperexpression of
ACE2 receptors (Angiotensin II receptor) in the cardiovascular system – it would
lead to a greater affinity of the virus for the cells of the cardiac system, causing
direct damage to the cells by SARS-CoV-2; (II) Myocardial damage caused by the
“Cytokine Storm” – with aggression from the immune system directly to the
cardiomyocyte cells; and (III) the Severe Acute Respiratory Distress syndrome
(ARDS) would cause hypoxemia, leading to myocardial ischemia [13]. Thus, preg-
nant women, due to the physiological overload of the cardiovascular system, theo-
retically, would have more severe cases of COVID-19.
Additionally, in the case of pregnant women, another factor should be consid-
ered: the immunotolerance changes in the innate and adaptive systems caused by
pregnancy (Figure 2). In the gestational immune system [14] there is a complex
humoral response in signaling. What happens is an alteration in the signaling pat-
tern, especially in CD4+ T lymphocytes. In this context, there is an important
decrease in the immune response by Th1 lymphocytes and an increase in the
response mediated by Th2 lymphocytes. In practice, this contributes to increased
maternal susceptibility to intracellular pathogens and viral infections, which causes
an increase in gestational morbidity in a broad and general way [15]. Thus, Th1 type
cytokines are pro-inflammatory agents that contain interleukins (IL-1a, IL-1b, IL-6,
IL-12) and interferon-gamma (IFN-g), while Th2 type cytokines are anti-
inflammatory drugs agents that contain interleukins (IL-4, IL-10, IL-13) and
transforming growth factor-beta (transforming growth factor β, TGF-β). Patients
with SARS-CoV-2 demonstrated preferential activation of Th1 immunity, resulting
in a considerable increase in pro-inflammatory cytokines for at least two weeks
after the onset of the disease, which would cause severe lung damage [13].
Consistent with literature data, pregnancy with the presence of Acute Respira-
tory Syndrome is more associated with maternal and neonatal complications such as
premature birth, intrauterine growth restriction, spontaneous abortion, orotracheal
intubation, ICU admissions, disseminated intravascular coagulation and acute renal
failure [16, 17]. A North American cohort that evaluated 8,207 pregnant women
with 83,205 women of childbearing age (15–44 years), both groups with laboratory
confirmation for SARS-CoV-2 showed a mortality rate lower than 1% (0.2% - being
16 pregnant and 208 not pregnant). The authors further report that pregnant
women had higher admission rates than their controls (31.5% vs. 5.8%, respec-
tively). In addition, pregnant women had a higher incidence of ICU admissions
compared to non-pregnant women (1.5% vs. 0.9%, respectively) and also had
greater need to use invasive mechanical ventilation (0.5% vs. 0.3%) [18]. A pro-
spective cohort conducted in Mexico through the “COVID-19 National Data Regis-
try of Mexico” compared 5,183 pregnant women with 175,905 non-pregnant women
with COVID-19 confirmed by RT-PCR. According to the authors, pregnant women
had higher odds ratios (OR) for deaths (1.84; 95%CI, 1.26–2.69), pneumonia (1.86;
95% CI, 1.60–2.16), and ICU admissions (1.86; 95%CI, 1.41–2.45) compared to non-
pregnant women [19].
In the context of SARS-COV-2, it seems that the clinical consequences caused by
COVID-19 are influenced by the patient’s age and pre-existing comorbidities [20].
Sentilhes et al. observed that women had one or more known maternal characteris-
tics associated with severe maternal morbidity, such as: age over 35 years, over-
weight, gestational hypertension, diabetes and preexisting asthma, which are
warning aspects for monitoring and managing pregnant women infected with
COVID-19 [21]. Study by Knight et al. showed that almost half (41% - 175) of
pregnant women with SARS-CoV-2 admitted to UK hospitals and evaluated in their
prospective cohort were at the age of 35 or over [22].
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A systematic review carried out in 2021 reported that, in general, patients with
non-communicable chronic diseases such as obesity, diabetes mellitus and systemic
arterial hypertension have higher morbidity and mortality rates when they acquire
COVID-19 compared to the general population [23]. In our study, approximately 80
and 50% of the pregnant patients were overweight or obese, respectively, before
pregnancy and had associated conditions, such as systemic arterial hypertension
(SAH). Obesity is considered an aggravating factor because it weakens lung func-
tion through mechanical and inflammatory pathways. In synergy with COVID-19,
obesity, asthma, and mechanical stress caused by high uterine volume can increase
the risk of premature birth [24]. Another study pointed out that 18.5% of pregnant
women had at least one comorbidity before pregnancy: asthma, SAH, or obesity
[21]. A cohort carried out in the United Kingdom based on the “UK Obstetric
Surveillance System” showed that of the 427 pregnant women admitted to hospital
units with SARS-CoV-2 infection, 69% (281) were overweight or obese and 34%
(145) had other pre-existing comorbidities. Around 10% of the admitted pregnant
women needed O2 support and 1% died [22]. However, it is not always possible to
determine the relationship between COVID-19 complications and the comorbidities
of pregnant women. In a study of 116 cases, of which nine patients (7.8%) had
gestational diabetes and five (4.3%) presented hypertensive disorders, including
pre-eclampsia, the authors indicated that there is not necessarily a direct
relationship between comorbidities and pregnancy complications associated with
COVID-19 [25].
The symptomatology of pregnant women with COVID-19 is not different from
that observed in the general population. A review study summarizes in Figure 3 the
main clinical manifestations of COVID-19 in pregnant women in epidemiological
studies:
Figure 3.
Main clinical manifestations of pregnant women with COVID-19 [adapted]. Source: Castro et al. [26].
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The data in Figure 3 are compatible with subsequent studies. A meta-analysis
carried out by an Italian group showed that the most common symptoms of
pregnant women with SARS-CoV-2, MERS and SARS were fever (82.6%), cough
(57.1%) and dyspnea (27.0%) [27]. Rasmussen et al. reported that the most
common symptoms of COVID-19 are fever, cough, myalgia, headache, and
diarrhea [28].
After analyzing 46 pregnant women with COVID-19 in a retrospective study,
most cases were treated in outpatient settings (78.3%, 36/46) or were asymptomatic
(6.5%, 3/46), with dyspnea being the main symptom. However, seven pregnant
patients (15.2%) were hospitalized due to COVID-19, one of whom was admitted to
the intensive care unit (ICU). The authors believe that pregnant women should be
considered a high-risk population for the severe form of COVID-19, particularly in
the second and third trimesters of pregnancy, especially if they are obese [24]. A
cross-sectional, descriptive and quantitative study carried out in the city of Wuhan,
China and published in the New England Journal of Medicine in April 2020, reports
that of the pregnant women who acquired COVID-19, 55 out of 106 (52%) were
nulliparous and 75 out of 118 (64%) had been infected with SARS-CoV-2 in the
third trimester. The most common symptoms in 112 women were fever (75%) and
cough (73%). Most (92%) had the disease in its mild form and 8% had hypoxemia
and severe forms, and of these patients one required intensive care support with
mechanical ventilation. Interestingly, COVID-19 was more severe among patients
in the immediate postpartum period [29].
The findings by Pierce-Williams et al. pointed out that, within the sample
universe analyzed, 73% of the pregnant women with severe manifestations of
COVID-19 required O2 supplementation, and 95% were intubated. Among women
with the severe form of the disease, 70% developed acute respiratory distress
syndrome (ARDS), 20% were placed in a prone position (in gestational ages at 26 to
31 weeks), and 20% required reintubation [9]. Systematic review conducted by
Juan et al. refers to seven maternal deaths, four intrauterine fetal deaths (one with
twin pregnancy) and two neonatal deaths (twin pregnancy) reported in a non-
consecutive case series of nine cases with severe COVID-19. In the case reports, two
maternal deaths, one neonatal death and two cases of neonatal SARS-CoV-2 infec-
tion were stated [30].
However, these findings are not unanimous in the literature. A cross-
sectional, descriptive and prospective study conducted in Utah, India, which
analyzed 65 pregnant women with positive RT-PCR for COVID-19, showed that
88.4% were asymptomatic [31]. An Iranian review study points out that preg-
nant women with comorbidities are more likely to have more severe clinical
pictures of COVID-19, although it is inconclusive for the authors that COVID-
19 alone can increase maternal-fetal risk [32]. A second review study published
in 2021 comparing outcomes between pregnant and non-pregnant women with
SARS-CoV-2, MERS (Middle East respiratory syndrome coronavirus) and SARS
(Severe acute respiratory syndrome coronavirus) concluded that there is no
evidence that pregnant women are more susceptible to coronavirus infection in
general, or that those infected with these viruses are more likely to develop
severe pneumonia. Similar to non-pregnant women, pregnant women with
MERS had the highest mortality, followed by those with SARS and COVID-19
[33]. These findings are corroborated by a retrospective and multicentric cohort
carried out in 2020 [34] in which it was observed that the mortality rate among
pregnant women (110 patients) compared to non-pregnant women (224
patients) did not show statistically significant differences. However, pregnant
women had lower saturation rates and global lymphocyte counts than their
peers in a statistically significant way.
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The prospective cohort study by Prabhu et al. analyzed 675 women admitted for
delivery, 10.4% tested positive for COVID-19, of whom 21.4% had at least one
symptom, demonstrating that there are significant outcome differences between
pregnant women who tested positive and negative for SARS-CoV-2 and symptom-
atic and asymptomatic ones. The rate of cesarean section was 15% higher among
women who were infected with the virus, in addition to demonstrating that post-
partum complications, including fever and hypoxia, occurred in 12.9% of the
women infected versus 4.5% of the women not infected. In that same study, pla-
cental perfusion diseases, possibly thrombi in fetal vessels, were frequent in
approximately 48% of the infected women [35].
The worsening of the clinical condition of pregnant women with COVID-19
raises great concern with potential outcomes that include spontaneous abortion,
premature birth, and fetal morbidity and mortality [24]. The severe consequences
for the fetus result from the oxygen supply deficit caused by maternal respiratory
disease, leading to hypoxemia due to the reduction of the partial pressure of oxygen
[14]. The study by Allotey J et al. showed that among pregnant women and recently
pregnant women with COVID-19, the chance of premature births was high com-
pared to pregnant women who did not have the disease [36].
A meta-analysis conducted by Mascio et al., which outlined complications
caused by coronavirus diseases, such as SARS, MERS, and COVID-19, in pregnant
women, found that those with COVID-19 had the highest incidence of premature
birth, achieving 41% against 24% for SARS. However, this group had the lowest
mortality rate (7%) [27, 35]. This low fetal mortality rate was corroborated by
studies such as that by Wong et al., in which SARS had a mortality rate of 25% and
induced abortions in up to 57% of the whole sample [17].
Furthermore, literature shows that advanced maternal age can be considered a
risk factor for the severe form of the disease during pregnancy [36]. In this scenario,
pregnant women over 35 years of age affected by COVID-19 require special atten-
tion [7, 37]. According to our data, the lethality rate among pregnant women with
SARS caused by COVID-19 in the 30–39 age group is 5.8%, increasing to 8.7% in the
40–49 age group, and exceeding 15% in the 50–59 age group.
4.1 Limitations
As biases in this study, those inherent in the secondary nature of the data should
be highlighted. First, the underreporting of cases - only people who sought health
services were notified. Consequently, mild or asymptomatic cases were not
counted; secondly, the dependence on correctly filling out the notification forms;
and, finally, the limited availability of information in the Brazilian Government’s
databases.
5. Conclusion
Comparing the lethality rate observed in pregnant women with SARS caused by
COVID-19 with that caused by other etiologic agents shows the severity of SARS-
CoV-2 in this group and that its potential for lethality is greater in the second
trimester of pregnancy. Likewise, it indicates that the older the age group, the
greater the lethality of the virus. In addition to the variables analyzed, other vari-
ables related to the presence of comorbidities and quality of care for pregnant
women should be considered in the model in future studies to determine the risk
level for these women and the required specialized conduct.
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